Biomed Research International-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-02-21 ms9000001886043195 来自浙江省

偏重的研究方向：生物信息学;免疫;肿瘤
经验分享：记录投稿 2023.2.7投稿

39 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-03-20 woshiliwj 来自浙江省

请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？

40 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2022-11-24 ms3000000517355402 来自山东省

审稿速度:12.0 | 投稿命中率:50.0
偏重的研究方向：网药
经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？

42 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2022-04-27 ms4000001680289394

成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted

111 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-01-22 少年宁来自浙江省

偏重的研究方向：生物信息学;肿瘤
经验分享：外审等Pending2个月了要不要问问编辑？

41 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-02-17 ms4000001921566004 来自北京

这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改

39 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-02-02 121122 来自江西省

期刊官网：https://www.hindawi.com/journals/bmri/
投稿链接：https://review.hindawi.com/submit?journal=bmri
作者指南：https://www.hindawi.com/journals/bmri/guidelines/

39 0

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2022-05-20 ms9000001270990329

偏重的研究方向：生物信息学;肿瘤
经验分享：从invited又变成submitted是怎么回事

79 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-02-22 韦钰来自山西省

审稿速度:2.0
偏重的研究方向：生物信息学;肿瘤
经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了

36 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2115823, encodeId=fc692115823e8, content=偏重的研究方向：生物信息学;免疫;肿瘤 经验分享：记录投稿 2023.2.7投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b59d8317671, createdName=ms9000001886043195, createdTime=Tue Feb 21 23:23:53 CST 2023, time=2023-02-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120646, encodeId=26e4212064677, content=请问有从别的杂志建议转投过来的吗？这样是不是被接收几率大一点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=feb71599658, createdName=woshiliwj, createdTime=Mon Mar 20 21:19:10 CST 2023, time=2023-03-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102431, encodeId=35362102431cf, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：网药 经验分享：请问有没有最近提交修正稿一直提交不上去，页面一直是Scanning for viruses吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb388133518, createdName=ms3000000517355402, createdTime=Thu Nov 24 16:27:15 CST 2022, time=2022-11-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215083, encodeId=1fcd12150838e, content=成分研究加网药 12月29号 Submitted 1月4号～3月11号 Submitted ~AE invited 3月12号 Reviewers Invited 3月21号 Under Review 3月28号 Pending Approval 4月6号 Submit Revision 4月22号 Under Review （只收到一个专家的意见） 4月24号 Pending Approval 4月27号 Accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Wed Apr 27 18:35:30 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2111167, encodeId=47bd211116eed, content=偏重的研究方向：生物信息学;肿瘤 经验分享：外审等Pending2个月了要不要问问编辑？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Jan 22 20:59:50 CST 2023, time=2023-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2115080, encodeId=b5a821150806a, content=这个杂志要几轮审稿呀，我返修以后一直会再送审，已经三轮了，又让修改, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4c8495856, createdName=ms4000001921566004, createdTime=Fri Feb 17 12:24:49 CST 2023, time=2023-02-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112756, encodeId=24262112e56b2, content=期刊官网：https://www.hindawi.com/journals/bmri/ 投稿链接：https://review.hindawi.com/submit?journal=bmri 作者指南：https://www.hindawi.com/journals/bmri/guidelines/, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e8d05141813, createdName=121122, createdTime=Thu Feb 02 16:21:44 CST 2023, time=2023-02-02, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1221239, encodeId=5a12122123992, content=偏重的研究方向：生物信息学;肿瘤 经验分享：从invited又变成submitted是怎么回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0de5720631, createdName=ms9000001270990329, createdTime=Fri May 20 17:18:52 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115914, encodeId=8a51211591439, content=审稿速度:2.0 偏重的研究方向：生物信息学;肿瘤 经验分享：1月初投的，一个月后邀请审稿人，然后一直持续这个状态一个月的样子，昨天突然收到拒稿，说是仔细检查文章后发现深度不够。……郁闷了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a7f5533568, createdName=韦钰, createdTime=Wed Feb 22 13:16:45 CST 2023, time=2023-02-22, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2113864, encodeId=19fe2113864fd, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;各科各门类 经验分享：请教一下大哥们，审稿人一般要邀请多久? , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e115631972, createdName=ms3000001193687879, createdTime=Thu Feb 09 21:36:15 CST 2023, time=2023-02-09, status=1, ipAttribution=江西省)]

2023-02-09 ms3000001193687879 来自江西省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：医学;各科各门类
经验分享：请教一下大哥们，审稿人一般要邀请多久?

70 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务